Literature DB >> 3965632

Correlation of chromosome abnormalities with patient characteristics, histologic subtype, and induction success in children with acute nonlymphocytic leukemia.

W G Woods, M E Nesbit, J Buckley, B C Lampkin, S McCreadie, T H Kim, S Piomelli, J H Kersey, S Feig, I Bernstein.   

Abstract

Cytogenetic analyses of bone marrow cells were performed in 195 children with acute nonlymphocytic leukemia (ANLL) at diagnosis, as part of Childrens Cancer Study Group Study No. 251. Ninety-six patients (49%) exhibited clonal abnormalities, including trisomy 8 in 18 patients, t(8;21) in 11, t(15;17) in seven, loss of a sex chromosome in seven, monosomy 7 in seven, and the Philadelphia chromosome in four. Clonal abnormalities were found significantly more often in younger patients. Furthermore, recurring cytogenetic abnormalities tended to correlate with specific ages. For example, t(8;21) was associated significantly with children over four years of age, while -7 associated with overall loss of genetic material from the long arm of chromosome 7 (7q) and 11q- were associated significantly with younger children. Recurring chromosome abnormalities also correlated with specific ANLL histologic subtypes, such as t(8;21) with acute myelogenous leukemia and t(15;17) with acute promyelocytic leukemia. Presence or absence of cytogenetic abnormalities was compared with the ability of patients to achieve remission. Individuals exhibiting clonal abnormalities in bone marrow cells had an equally likely chance of achieving remission (74%) as those individuals with normal karyotypes (75%). Nonrandom chromosome abnormalities associated with a high induction success rate included +8 with a 94% induction success rate (P = .13) and t(8;21) with a 91% success rate (P = .46). Patients exhibiting the -7 abnormality associated with overall loss of 7q had a significantly less successful induction outcome, with only 28% achieving remission (P = .02); three of seven patients with t(15;17) died during induction therapy.

Entities:  

Mesh:

Year:  1985        PMID: 3965632     DOI: 10.1200/JCO.1985.3.1.3

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  6 in total

1.  A case of congenital leukemia with monosomy 7.

Authors:  T Shitara; N Suetake; S Yugami; M Sotomatu; Y Oshima; H Ijima; T Kuroume; S Nakazawa
Journal:  Ann Hematol       Date:  1992-12       Impact factor: 3.673

Review 2.  Acute myelogenous leukaemia in children.

Authors:  S O Lie
Journal:  Eur J Pediatr       Date:  1989-02       Impact factor: 3.183

Review 3.  Genetic markers on chromosome 7.

Authors:  L C Tsui
Journal:  J Med Genet       Date:  1988-05       Impact factor: 6.318

4.  Leukaemia and transient leukaemia in Down syndrome.

Authors:  L Iselius; P Jacobs; N Morton
Journal:  Hum Genet       Date:  1990-10       Impact factor: 4.132

5.  Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group.

Authors:  Beverly J Lange; Franklin O Smith; James Feusner; Dorothy R Barnard; Patricia Dinndorf; Stephen Feig; Nyla A Heerema; Carola Arndt; Robert J Arceci; Nita Seibel; Margie Weiman; Kathryn Dusenbery; Kevin Shannon; Sandra Luna-Fineman; Robert B Gerbing; Todd A Alonzo
Journal:  Blood       Date:  2007-11-13       Impact factor: 22.113

6.  Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.

Authors:  Ying Jiang; Andrew Dunbar; Lukasz P Gondek; Sanjay Mohan; Manjot Rataul; Christine O'Keefe; Mikkael Sekeres; Yogen Saunthararajah; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2008-10-02       Impact factor: 22.113

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.